title: Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre.
abstract: <bold>Objective:</bold> To determine the efficacy and safety of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) patients from the named patient programme (NPP) at our centre. <bold>Methods:</bold> mCRPC patients who progressed on docetaxel were given cabazitaxel intravenously every 3 weeks until disease progression or unacceptable toxicity occurred. Overall survival, progression-free survival, prostate-specific antigen response, quality of life (QOL) changes, and safety were reported. <bold>Results:</bold> Nine men received cabazitaxel (median: 7 cycles; range: 1-27) under the NPP and were followed until death. Median survival was 14.07 months (1.07-23.80) and progression-free survival was 2.67 months (1.07-20.27). QOL was stable for most patients. Common adverse events (grade ≥3) were neutropenia (n = 8), anaemia (n = 4), and leucopenia (n = 4). <bold>Conclusion:</bold> These data from 9 patients are consistent with the results reported in the TROPIC study with a manageable safety profile.
authors.affiliation: Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
authors.forename: Vanita
authors.initials: V
authors.lastname: Noronha
authors.affiliation: Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
authors.forename: Amit
authors.initials: A
authors.lastname: Joshi
authors.affiliation: Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
authors.forename: Vamshi Krishna
authors.initials: VK
authors.lastname: Muddu
authors.affiliation: Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
authors.forename: Vijay
authors.initials: V
authors.lastname: Maruti Patil
authors.affiliation: Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
authors.forename: Kumar
authors.initials: K
authors.lastname: Prabhash
keywords: Cabazitaxel; Disease-free survival; Leucopenia; Neutropenia; Prostate-specific antigen